Does the media prefer VKTX or MGTX?

In the previous week, Viking Therapeutics had 10 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Viking Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Viking Therapeutics' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGTX or ACAD?

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 0.83 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MGTX or EWTX?

In the previous week, Edgewise Therapeutics had 3 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Edgewise Therapeutics' score of 0.66 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGTX or TNGX?

In the previous week, Tango Therapeutics had 5 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Tango Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Tango Therapeutics' score of 0.35 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, MGTX or NAMS?

MeiraGTx has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 14.34 -$114.20M -$1.48 N/A NewAmsterdam Pharma $22.50M 161.04 -$203.82M -$1.79 N/A

Does the media refer more to MGTX or NAMS?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat NewAmsterdam Pharma's score of 0.51 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MeiraGTx (MGTX) Competitors

$12.60 +0.40 (+3.24%)

As of 12:03 PM Eastern

Compare

MGTX vs. VKTX, ACAD, EWTX, TNGX, and NAMS

Should you buy MeiraGTx stock or one of its competitors? MarketBeat compares MeiraGTx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MeiraGTx include Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does MeiraGTx compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and MeiraGTx (NASDAQ:MGTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Viking Therapeutics currently has a consensus target price of $93.60, indicating a potential upside of 150.98%. MeiraGTx has a consensus target price of $26.00, indicating a potential upside of 106.27%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Viking Therapeutics had 10 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Viking Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Viking Therapeutics' score of 0.28 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viking Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
MeiraGTx	-151.12%	N/A	-54.96%

MeiraGTx has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
MeiraGTx	$81.39M	14.34	-$114.20M	-$1.48	N/A

Summary

MeiraGTx beats Viking Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to ACADIA Pharmaceuticals?

MeiraGTx (NASDAQ:MGTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.34	-$114.20M	-$1.48	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.41

MeiraGTx currently has a consensus price target of $26.00, suggesting a potential upside of 106.27%. ACADIA Pharmaceuticals has a consensus price target of $33.17, suggesting a potential upside of 32.16%. Given MeiraGTx's stronger consensus rating and higher possible upside, equities analysts clearly believe MeiraGTx is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.67

MeiraGTx has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 10 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for ACADIA Pharmaceuticals and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat ACADIA Pharmaceuticals' score of 0.83 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to MeiraGTx's net margin of -151.12%. ACADIA Pharmaceuticals' return on equity of 9.61% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Summary

ACADIA Pharmaceuticals beats MeiraGTx on 11 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Edgewise Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Edgewise Therapeutics had 3 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Edgewise Therapeutics' score of 0.66 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

MeiraGTx has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.34	-$114.20M	-$1.48	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

MeiraGTx currently has a consensus price target of $26.00, indicating a potential upside of 106.27%. Edgewise Therapeutics has a consensus price target of $48.75, indicating a potential upside of 23.98%. Given MeiraGTx's higher probable upside, analysts plainly believe MeiraGTx is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MeiraGTx beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Tango Therapeutics?

MeiraGTx (NASDAQ:MGTX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Tango Therapeutics had 5 more articles in the media than MeiraGTx. MarketBeat recorded 6 mentions for Tango Therapeutics and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat Tango Therapeutics' score of 0.35 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tango Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
Tango Therapeutics	N/A	-41.54%	-33.44%

MeiraGTx presently has a consensus target price of $26.00, suggesting a potential upside of 106.27%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 46.28%. Given MeiraGTx's higher probable upside, equities research analysts clearly believe MeiraGTx is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

MeiraGTx has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Tango Therapeutics has lower revenue, but higher earnings than MeiraGTx. Tango Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.34	-$114.20M	-$1.48	N/A
Tango Therapeutics	$62.38M	66.82	-$101.59M	-$0.83	N/A

Summary

MeiraGTx and Tango Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does MeiraGTx compare to NewAmsterdam Pharma?

MeiraGTx (NASDAQ:MGTX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

MeiraGTx has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	14.34	-$114.20M	-$1.48	N/A
NewAmsterdam Pharma	$22.50M	161.04	-$203.82M	-$1.79	N/A

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for NewAmsterdam Pharma and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.17 beat NewAmsterdam Pharma's score of 0.51 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MeiraGTx currently has a consensus price target of $26.00, indicating a potential upside of 106.27%. NewAmsterdam Pharma has a consensus price target of $49.42, indicating a potential upside of 59.43%. Given MeiraGTx's higher possible upside, research analysts plainly believe MeiraGTx is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

MeiraGTx has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

MeiraGTx has a net margin of -151.12% compared to NewAmsterdam Pharma's net margin of -943.23%. MeiraGTx's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-151.12%	N/A	-54.96%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

MeiraGTx beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$3.64B	$6.80B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-8.52	20.63	27.05	24.17
Price / Sales	14.34	304.98	517.90	92.83
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	-180.07	8.05	10.65	6.23
Net Income	-$114.20M	$23.81M	$3.59B	$331.42M
7 Day Performance	1.33%	-1.53%	-0.84%	-1.22%
1 Month Performance	11.35%	2.16%	1.42%	-1.36%
1 Year Performance	45.05%	44.29%	24.75%	18.43%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	3.8278 of 5 stars	$12.61 +3.2%	$26.00 +106.3%	+41.6%	$1.17B	$81.39M	N/A	300	Positive News
VKTX Viking Therapeutics	3.1143 of 5 stars	$37.60 -1.4%	$93.60 +148.9%	+13.7%	$4.37B	N/A	N/A	20
ACAD ACADIA Pharmaceuticals	4.8512 of 5 stars	$25.34 -0.6%	$32.94 +30.0%	+11.2%	$4.34B	$1.07B	11.51	510	Analyst Forecast
EWTX Edgewise Therapeutics	3.1668 of 5 stars	$39.46 -4.4%	$47.92 +21.4%	+186.6%	$4.25B	N/A	N/A	60	Analyst Forecast
TNGX Tango Therapeutics	2.5428 of 5 stars	$28.67 +1.1%	$41.50 +44.7%	+306.8%	$4.15B	$62.38M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does MeiraGTx compare to Viking Therapeutics?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Summary

How does MeiraGTx compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does MeiraGTx compare to Viking Therapeutics?

Which has more risk and volatility, VKTX or MGTX?

Do analysts prefer VKTX or MGTX?

Do institutionals and insiders believe in VKTX or MGTX?

Does the media prefer VKTX or MGTX?

Is VKTX or MGTX more profitable?

Which has preferable earnings & valuation, VKTX or MGTX?

Summary

How does MeiraGTx compare to ACADIA Pharmaceuticals?

Which has preferable valuation & earnings, MGTX or ACAD?

Do analysts recommend MGTX or ACAD?

Which has more risk and volatility, MGTX or ACAD?

Does the media refer more to MGTX or ACAD?

Do insiders & institutionals have more ownership in MGTX or ACAD?

Is MGTX or ACAD more profitable?

Summary

How does MeiraGTx compare to Edgewise Therapeutics?

Does the media favor MGTX or EWTX?

Which has more risk & volatility, MGTX or EWTX?

Which has preferable earnings and valuation, MGTX or EWTX?

Is MGTX or EWTX more profitable?

Do analysts recommend MGTX or EWTX?

Do insiders and institutionals have more ownership in MGTX or EWTX?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Does the media refer more to MGTX or TNGX?

Do insiders & institutionals believe in MGTX or TNGX?

Is MGTX or TNGX more profitable?

Do analysts prefer MGTX or TNGX?

Which has more risk & volatility, MGTX or TNGX?

Which has better earnings & valuation, MGTX or TNGX?

Summary

How does MeiraGTx compare to NewAmsterdam Pharma?

Which has better earnings and valuation, MGTX or NAMS?

Do institutionals & insiders have more ownership in MGTX or NAMS?

Does the media refer more to MGTX or NAMS?

Do analysts rate MGTX or NAMS?

Which has more volatility and risk, MGTX or NAMS?

Is MGTX or NAMS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools